Phenotypes associated with this allele

• Allele Symbol: Gpam^tm1Rcol
• Allele Name: targeted mutation 1, Rosalind Coleman
• Allele ID: MGI:2669956
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Gpam^tm1Rcol/Gpam^tm1Rcol	involves: 129S6/SvEvTac * C57BL/6J	MGI:2669972

Genotype
MGI:2669972

hm1

• Allelic Composition: Gpam^tm1Rcol/Gpam^tm1Rcol
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

decreased body weight ( J:84541 )

• female homozygotes weigh 6% and 20% less than wild-type controls at 5 and 10 months, respectively

• although weights of male homozygotes do not differ significantly by genotype, pooled weight data indicates a significant effect of genotype, with mutant mice weighing less than wild-type controls

slow postnatal weight gain ( J:84541 )

• when fed a diet containing 14% kcal from fat, homozygotes gain less weight than control mice, as determined by body weights at 2, 5, 8, and 10 months of age

adipose tissue

decreased gonadal fat pad weight ( J:84541 )

• at 12 months of age, homozygotes display reduced gonadal fat pad weight relative to wild-type controls

decreased percent body fat/body weight ( J:84541 )

• at 12 months of age, homozygotes display less fat than wild-type controls as a percentage of total body weight

homeostasis/metabolism

decreased circulating insulin level ( J:84541 )

• at 2 months of age, homozygotes display a trend toward reduced plasma insulin levels, suggesting increased insulin sensitivity

abnormal lipid homeostasis ( J:84541 )

• in mutant liver, the palmitate content is lower in triacylglycerol, phosphatidylcholine, and phosphatidylethanolamine

• in mutant liver, phosphatidylethanolamine and phosphatidylcholine contains about 21% less palmitate in the sn-1 position and 36 and 40%, respectively, more arachidonate in the sn-2 position

decreased circulating cholesterol level ( J:84541 )

• at 2 months of age, homozygotes display significantly lower total plasma cholesterol levels relative to control mice

decreased circulating HDL cholesterol level ( J:84541 )

• at 2 months of age, female homozygotes display reduced plasma HDL cholesterol levels relative to control mice

decreased circulating triglyceride level ( J:84541 )

• at 2 months of age, female homozygotes show a 15% reduction in plasma triacylglycerol levels relative to control mice

• reduced plasma triacylglycerol levels are due to a 30% decrease in VLDL secretion rate

decreased circulating VLDL triglyceride level ( J:84541 )

• at 2 months of age, female homozygotes display reduced VLDL triacylglycerol levels relative to control mice

abnormal fatty acids level ( J:84541 )

• homozygotes display changes in fatty acid content of triacylglycerol and cholesterol esters, and altered positioning of specific fatty acids, particularly palmitate and arachidonate, in phospholipids

decreased liver triglyceride level ( J:84541 )

• at 2 months of age, female homozygotes show a 37% reduction in liver triacylglycerol content relative to control mice

• in contrast, hepatic cholesterol and phospholipid contents remain normal

liver/biliary system

decreased liver triglyceride level ( J:84541 )

• at 2 months of age, female homozygotes show a 37% reduction in liver triacylglycerol content relative to control mice

• in contrast, hepatic cholesterol and phospholipid contents remain normal